GenVec Inc. (NASDAQ:GNVC) has earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus target price of $2.15 for the company and are predicting that the company will post ($0.08) EPS for the current quarter, according to Zacks. Zacks has also assigned GenVec an industry rank of 111 out of 265 based on the ratings given to related companies.

Several equities analysts have weighed in on GNVC shares. Zacks Investment Research raised GenVec from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research report on Thursday, July 28th. Roth Capital reaffirmed a “buy” rating and issued a $2.00 target price (down from $8.00) on shares of GenVec in a research report on Tuesday, July 26th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and issued a $2.30 target price on shares of GenVec in a research report on Monday, June 20th.

A hedge fund recently bought a new stake in GenVec stock. Sabby Management LLC acquired a new position in GenVec Inc. (NASDAQ:GNVC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,625,435 shares of the biopharmaceutical company’s stock, valued at approximately $931,000. Sabby Management LLC owned about 7.15% of GenVec at the end of the most recent reporting period. Institutional investors and hedge funds own 26.79% of the company’s stock.

GenVec (NASDAQ:GNVC) opened at 0.4299 on Friday. The company has a 50 day moving average of $0.52 and a 200 day moving average of $0.63. GenVec has a 12 month low of $0.35 and a 12 month high of $3.69. The stock’s market capitalization is $9.77 million.

GenVec (NASDAQ:GNVC) last issued its quarterly earnings data on Friday, August 5th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.04. GenVec had a negative net margin of 927.05% and a negative return on equity of 83.14%. On average, equities analysts predict that GenVec will post ($0.29) EPS for the current year.

About GenVec

GenVec, Inc (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria.

5 Day Chart for NASDAQ:GNVC

Get a free copy of the Zacks research report on GenVec (GNVC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for GenVec Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec Inc. and related companies with's FREE daily email newsletter.